Showing results (111-120 of 144) with videos related to
Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|August 19, 2023
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapyHua Zhong, Xueyan Zhang, Panwen Tian, et al.Cell Death and Differentiation|September 28, 2022
Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancerKaixuan Shi, Haijiao Lu, Zhenfeng Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancerDingzhi Huang, Yi Ba, Jianping Xiong, et al.BMC Cancer|July 5, 2017
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)Qing Zhou, Yong Song, Xin Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)Yong Song, Qing Zhou, Xin Zhang, et al.Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 8, 2013
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]Ding-zhi Huang, Jian-ping Xiong, Nong Xu, et al.Journal of Chemotherapy (Florence, Italy)|February 26, 2013
Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trialTing Deng, Nong Xu, Jian-Ping Xiong, et al.Cancer Research and Treatment|July 29, 2026
Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 TrialWei Ren, Xiuping Lai, Guiying Bai, et al.The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.Cancer Letters|January 12, 2025
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIsXinjun Tang, Jie Hu, Renhua Guo, et al.Pageof 15